NL-OMON38629已完成不适用
A PHASE 1, OPEN-LABEL STUDY OF THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF 14C-LABELED IPI-145 AND THE ABSOLUTE BIOAVAILABILITY OF IPI-145 IN HEALTHY SUBJECTS - IPI-145 ADME and absolute bioavailability study
Infinity Pharmaceuticals0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age: 18-45 years, inclusive
- •Gender: Male
- •BMI: 18.0-30.0 kg/m2
排除标准
- •Suffering from: hepatitis B, C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1.5 liter (for men)/ 1.0 liter (for women) of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
1 期
Mass Balance Study of [14C]-S-600918 Oral Suspension in Healthy Male SubjectsHealthy subjectsJPRN-jRCT1080225285Shionogi B.V.6
已完成
不适用
A phase 1, open-label study to assess the absorption, metabolism, and excretion, including the mass balance, of a single oral dose of [14C]-etrumadenant in healthy male subjectsCancer, tumorstumorsCancerNL-OMON51599Arcus Biosciences, Inc.8
已完成
1 期
A study to see how [14C]-S-033188 is taken up, broken down and removed from the bodyRespiratoryInfluenza, virus not identifiedInfluenza virus infectionISRCTN74587134Shionogi Ltd6
已完成
1 期
A study evaluating the absorption, metabolism, and excretion of [14C]-GDC-6036 following a single oral dose in healthy male participantsISRCTN10152571F. Hoffmann-La Roche (Switzerland)8
已完成
不适用
A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of Radiolabeled [14C] R924548 Following Single Oral Dose Administration in Healthy Male Subjectsimmune-mediated diseasesrheuma10003816NL-OMON37118Rigel Pharmaceuticals, Inc6